Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of stock-based compensation expense related to all of the entity's share-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and nine months ended September 30, 2016 and 2015 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
Research and development	$	643	$	966	$	2,746	$	3,182
General and administrative		572		849		1,921		2,596
Restructuring charges		499		—		499		—
Total stock-based compensation expense	$	1,714	$	1,815	$	5,166	$	5,778

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended			Nine Months Ended
	September 30,			September 30,
	2016	2015		2016		2015
Risk-free interest rate	—	1.9	%	1.7	%	1.8	%
Expected term (in years)	—	6.0		6.4		6.5
Dividend yield	—	0.0	%	0.0	%	0.0	%
Expected volatility	—	59.6	%	63.3	%	65.0	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Nine Months Ended
	September 30,
	2016		2015
Risk-free interest rate	0.5	%	0.6	%
Expected term (in years)	1.5		1.5
Dividend yield	0.0	%	0.0	%
Expected volatility	63.0	%	61.2	%